• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • Myinsights
  • MYBoard
  • Strategy & Consulting
Select Page

Durvalumab Regimen Improves Disease-Free Survival in High-Risk Non-Muscle-Invasive Bladder Cancer

by MM360 Staff | May 16, 2025 | Myeloma News | 0 comments

Source: Pharmacy Times articles

The regimen, which consists of durvalumab and Bacillus Calmette-Guerin, offers new hope to patients with high-risk non-muscle-invasive bladder cancer.
Read More

Submit a Comment Cancel reply

You must be logged in to post a comment.

Recent Content

  • 2025 Quarter 1 – COA Patient Advocacy Network News Bulletin.
  • EPA Deregulation Means More Air Pollution and More Cancer Deaths
  • FDA Approved NDA for Aficamten to Treat Patients With Obstructive Hypertrophic Cardiomyopathy
  • Understanding Unique Treatment Options Across Bladder Cancer Care
  • Evaluation of Antibiotic Administration Surrounding Interventional Radiology Procedures
  • Brain Cancer Awareness Month Highlights Advances in Radiation Therapy
  • Adding Pertuzumab to Trastuzumab and Chemotherapy Reduced Risk of Death by 17% in HER2+ Breast Cancer
  • Several Comorbidities Found to Reduce Likelihood of Pneumococcal Vaccination, While Use of Implantable Devices Heightens Odds
  • Omalizumab: An All-in-One Allergy Wonder Drug?
  • Durvalumab Regimen Improves Disease-Free Survival in High-Risk Non-Muscle-Invasive Bladder Cancer
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT